Browse studies

Find your next paid study

192 recruiting studies matching your filters

Newest first Highest paying

Phase 1

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia and Other Selected Hematologic Malignancies, With and Without Mixed Lineage Leukemia (MLL) Rearrangement or Nucleophosmin 1 (NPM1) Mutation (Horizen-1)

A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, AcuteMultiple Myeloma+1 more

Estimated

~$10 – $8,750

Sumitomo Pharma America, Inc.NCT04988555

Phase 2

A Phase II Trial of High Dose Ascorbate in Combination With Azacitidine in Adults With Myelodysplastic Syndrome

This is an open-label, phase II clinical trial with safety run-in evaluating the safety, tolerability, and efficacy of IV HDA in combination with azacitidine f…

Myelodysplastic Syndromes

Estimated

~$10 – $7,500

Prajwal DhakalNCT07283900

The Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform Program (SDS-GPS Program)

The Shwachman-Diamond Syndrome Global Patient Survey and Collaboration Program (SDS-GPS) is an opportunity for patients and their families - from anywhere in t…

Shwachman-Diamond SyndromeSDSIBMF+24 more

Estimated

~$10 – $1,050

Shwachman-Diamond Syndrome Alliance IncNCT06999954

Phase 2

A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity Conditioning

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopo…

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAdult T-Cell Leukemia/Lymphoma+14 more

Estimated

~$10 – $6,250

Thomas Jefferson UniversityNCT05031897

Phase 1

A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in th…

Myelodysplastic Syndromes

Estimated

~$10 – $8,750

Syntrix Biosystems, Inc.NCT04245397

Phase 1

A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies

This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, inclu…

Myelodysplastic Syndromes, de NovoMyelodysplastic Syndromes, SecondaryMyelodysplastic Syndromes, Previously Treated+8 more

The Impact of a Non-Profit Cancer Advocacy Organization on Patient Reported Outcomes and Access to Care: A Multisite, Longitudinal Trial

The purpose of this study is to learn about the impact that the services and programs provided by Blood Cancer United (formerly, The Leukemia and Lymphoma Soci…

LeukemiaLymphomaMyeloma+2 more

Estimated

~$10 – $6,250

University of MiamiNCT05745285

Phase 2

A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients With Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Transplantation Cyclophosphamide (PTCy)

This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in…

Acute LeukemiaAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+2 more

Estimated

~$10 – $6,250

Fred Hutchinson Cancer CenterNCT03970096

Phase 1

Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to ma…

Acute Myeloid LeukemiaChronic Myeloid LeukemiaAcute Lymphoblastic Leukemia+1 more

Estimated

~$10 – $6,250

University of Kansas Medical CenterNCT03533816

Phase 2

A Multi-phase, Pharmacokinetics, Safety, and Efficacy Study of ASTX030 (Azacitidine and Cedazuridine) as Monotherapy in Subjects With Myeloid Neoplasm or in Combination With Venetoclax in Subjects With AML (AZTOUND Study)

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consis…

Myelodysplastic SyndromesAcute Myeloid LeukemiaMyelodysplastic Syndrome/Neoplasm+1 more

Estimated

~$10 – $8,750

Taiho Oncology, Inc.NCT04256317

Observational

A Prospective Study of Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS

This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physi…

Whole Genome SequencingMyelodysplastic Syndromes

Estimated

~$10 – $6,250

Washington University School of MedicineNCT05434598

Phase 1

A Phase 1/2, Open-label, Multicenter Trial to Assess the Safety and Efficacy of ARD103 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

This is a phase I/2, interventional, open-label, multicenter study to assess the safety and efficacy of ARD103 in patients with relapsed or refractory acute my…

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia RefractoryMDS (Myelodysplastic Syndrome)

Estimated

~$10 – $8,750

ARCE Therapeutics, Inc.NCT06680752